BB3008 / BroadenBio - LARVOL DELTA

A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Active, not recruiting | Sponsor: Broadenbio Ltd., Co. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Nov 2025 ➔ May 2025

Enrollment closed • Trial primary completion date • Solid Tumor

A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: BrodenBio Co., Ltd.

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: BrodenBio Co., Ltd.

New P1 trial • Oncology • Solid Tumor

BB3008, a potent and selective small molecular HPK1 inhibitor effective in multiple syngeneic tumor models (AACR 2023) - "As a potent, selective and oral available small molecule HPK1 inhibitor, BB3008 shows good safety tolerance in preclinical animals, and promising efficacy in multiple solid tumor models, both as single agent or in combination with immune checkpoint blockade. The IND-enabling study of BB3008 is in progress."

IO biomarker • Late-breaking abstract • Preclinical • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • IL2 • LCP2 • ZAP70